Regulatory Recon is our regular intelligence briefing for the regulatory affairs space, bringing you the top regulatory, ...
Several patient and disease advocacy organizations have responded to the Center for Drug Evaluation and Research's (CDER) ...
The US Food and Drug Administration (FDA) has announced that starting on 1 October 2026, manufacturers must submit adverse ...
Hong Kong’s Department of Health (DH) has begun a phased transition to the independent assessment of primary data on new ...
Welcome to another installment of This Week at FDA, your weekly source for updates – big and small – on FDA, drug and medical device regulation, and what we’re reading from around the web. This week, ...
Welcome to another installment of This Week at FDA, your weekly source for updates – big and small – on FDA, drug and medical device regulation, and what we’re reading from around the web. This week, ...
A new RAPS digital experience is coming! Parts of our website will be inaccessible between Saturday, 28 March and Wednesday, 1 April during the migration. These services include: the RAPS Marketplace, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results